Hunan Jingfeng Pharmaceutical Co.,Ltd.

Symbol: 000908.SZ

SHZ

2.07

CNY

Market price today

  • -6.8734

    P/E Ratio

  • -0.0686

    PEG Ratio

  • 1.82B

    MRK Cap

  • 0.00%

    DIV Yield

Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908-SZ) Stock Price & Analysis

Shares Outstanding

879.77M

Gross Profit Margin

0.69%

Operating Profit Margin

-0.31%

Net Profit Margin

-0.37%

Return on Assets

-0.19%

Return on Equity

-4.27%

Return on Capital Employed

-8.16%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Xiang Wu Ye
Full-time employees:645
City:Shanghai
Address:No. 50, Luoxin Road
IPO:1999-02-03
CIK:

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. The company was founded in 2003 and is headquartered in Shanghai, China.

General Outlook

In simple terms, Hunan Jingfeng Pharmaceutical Co.,Ltd. has 879.774 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.691% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.307%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.366%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.194% return, is a testament to Hunan Jingfeng Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. Hunan Jingfeng Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -4.272%. Furthermore, the proficiency of Hunan Jingfeng Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable -8.157% return on capital employed.

Stock Prices

Hunan Jingfeng Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.27, while its low point bottomed out at $2.27. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Hunan Jingfeng Pharmaceutical Co.,Ltd.'s stock market.

Liquidity Ratios

Analyzing 000908.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 24.01% gauges short-term asset coverage for liabilities. The quick ratio (-20.96%) assesses immediate liquidity, while the cash ratio (-30.03%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio24.01%
Quick Ratio-20.96%
Cash Ratio-30.03%

Profitability Ratios

000908.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -30.84% underscores its earnings before tax deductions. The effective tax rate stands at -17.27%, revealing its tax efficiency. The net income per EBT, 118.76%, and the EBT per EBIT, 100.33%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -30.74%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-30.84%
Effective Tax Rate-17.27%
Net Income per EBT118.76%
EBT per EBIT100.33%
EBIT per Revenue-30.74%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.24, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding-21
Days of Inventory Outstanding129
Operating Cycle190.72
Days of Payables Outstanding336
Cash Conversion Cycle-145
Receivables Turnover5.94
Payables Turnover1.09
Inventory Turnover2.82
Fixed Asset Turnover1.37
Asset Turnover0.53

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.03, and free cash flow per share, 0.03, depict cash generation on a per-share basis. The cash per share value, -0.37, showcases liquidity position. A payout ratio of -0.09 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.05, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.03
Free Cash Flow per Share0.03
Cash per Share-0.37
Payout Ratio-0.09
Operating Cash Flow Sales Ratio0.05
Free Cash Flow to Operating Cash Flow Ratio0.81
Cash Flow Coverage Ratio0.05
Short Term Coverage Ratio0.06
Capital Expenditure Coverage Ratio5.19
Dividend Paid and Capex Coverage Ratio1.16
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 53.68%, highlights its total liabilities relative to assets. With a debt-equity ratio of -12.84, we discern the balance between debt and equity financing. The long-term debt to capitalization, 195.84%, and total debt to capitalization, 108.44%, ratios shed light on its capital structure. An interest coverage of -4.54 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio53.68%
Debt Equity Ratio-12.84
Long Term Debt to Capitalization195.84%
Total Debt to Capitalization108.44%
Interest Coverage-4.54
Cash Flow to Debt Ratio0.05
Company Equity Multiplier-23.93

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.75, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.24, reflects the portion of profit attributed to each share. The book value per share, -0.06, represents the net asset value distributed per share, while the tangible book value per share, -0.37, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.75
Net Income Per Share-0.24
Book Value Per Share-0.06
Tangible Book Value Per Share-0.37
Shareholders Equity Per Share-0.06
Interest Debt Per Share0.72
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -21.86%, indicates top-line expansion, while the gross profit growth, -26.46%, reveals profitability trends. EBIT growth, -1295.33%, and operating income growth, -1295.33%, offer insights into operational profitability progression. The net income growth, -113.25%, showcases bottom-line expansion, and the EPS growth, -118.18%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-21.86%
Gross Profit Growth-26.46%
EBIT Growth-1295.33%
Operating Income Growth-1295.33%
Net Income Growth-113.25%
EPS Growth-118.18%
EPS Diluted Growth-118.18%
Weighted Average Shares Growth0.02%
Weighted Average Shares Diluted Growth0.02%
Dividends per Share Growth-40.44%
Operating Cash Flow Growth-71.55%
Free Cash Flow Growth-77.55%
10-Year Revenue Growth per Share128.85%
5-Year Revenue Growth per Share-74.60%
3-Year Revenue Growth per Share-25.19%
10-Year Operating CF Growth per Share693.74%
5-Year Operating CF Growth per Share-90.01%
3-Year Operating CF Growth per Share112.90%
10-Year Net Income Growth per Share-3822.05%
5-Year Net Income Growth per Share-215.14%
3-Year Net Income Growth per Share81.38%
10-Year Shareholders Equity Growth per Share-683.72%
5-Year Shareholders Equity Growth per Share-101.99%
3-Year Shareholders Equity Growth per Share-109.52%
10-Year Dividend per Share Growth per Share-74.05%
5-Year Dividend per Share Growth per Share-76.89%
3-Year Dividend per Share Growth per Share-73.55%
Receivables Growth-63.15%
Inventory Growth-46.35%
Asset Growth-27.79%
Book Value per Share Growth-127.81%
Debt Growth-0.82%
R&D Expense Growth47.31%
SGA Expenses Growth-8.64%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,475,701,467.04, captures the company's total value, considering both debt and equity. Income quality, -0.17, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.14, gauges operational efficiency, while the research and development to revenue, 7.99%, highlights investment in innovation. The ratio of intangibles to total assets, 15.88%, indicates the value of non-physical assets, and capex to operating cash flow, -29.72%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,475,701,467.04
Income Quality-0.17
Sales General and Administrative to Revenue0.14
Research and Development to Revenue7.99%
Intangibles to Total Assets15.88%
Capex to Operating Cash Flow-29.72%
Capex to Revenue-1.59%
Capex to Depreciation-23.44%
Graham Number0.56
Return on Tangible Assets-24.12%
Graham Net Net-1.25
Working Capital-827,785,585
Tangible Asset Value-322,015,649
Net Current Asset Value-1,000,269,583
Invested Capital-12
Average Receivables159,546,823.5
Average Payables143,739,440
Average Inventory92,472,894.5
Days Sales Outstanding48
Days Payables Outstanding293
Days of Inventory On Hand127
ROIC-37.77%
ROE4.35%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -31.83, and the price to book ratio, -31.83, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.53, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 60.50, and price to operating cash flows, 48.64, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-31.83
Price to Book Ratio-31.83
Price to Sales Ratio2.53
Price Cash Flow Ratio48.64
Price Earnings to Growth Ratio-0.07
Enterprise Value Multiple-9.45
Price Fair Value-31.83
Price to Operating Cash Flow Ratio48.64
Price to Free Cash Flows Ratio60.50
Price to Tangible Book Ratio-58.49
Enterprise Value to Sales5.29
Enterprise Value Over EBITDA-620.18
EV to Operating Cash Flow99.12
Earnings Yield-7.43%
Free Cash Flow Yield0.85%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -6.873 in 2024.

What is the ticker symbol of Hunan Jingfeng Pharmaceutical Co.,Ltd. stock?

The ticker symbol of Hunan Jingfeng Pharmaceutical Co.,Ltd. stock is 000908.SZ.

What is company IPO date?

IPO date of Hunan Jingfeng Pharmaceutical Co.,Ltd. is 1999-02-03.

What is company current share price?

Current share price is 2.070 CNY.

What is stock market cap today?

The market cap of stock today is 1821132180.000.

What is PEG ratio in 2024?

The current -0.069 is -0.069 in 2024.

What is the number of employees in 2024?

In 2024 the company has 645.